La Rosa Holdings Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by La Rosa Holdings Corp. (Nasdaq: LRHC) on April 17, 2024. The report discloses significant changes to the composition of the Company's Board of Directors, specifically the resignation of a director and the appointment of a new independent director.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
- Resignation: Thomas Stringer resigned as a member of the Board of Directors, effective immediately on April 17, 2024. Mr. Stringer previously served as Chairman and "financial expert" of the Audit Committee, and as a member of the Compensation and Nominating and Corporate Governance Committees. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Lourdes Felix was appointed as a member of the Board, effective April 19, 2024. She was also appointed as Chairperson and "financial expert" of the Audit Committee, and as a member of the Compensation and Nominating Committees.
- Independence: The Board determined that Ms. Felix qualifies as an "independent director" under Nasdaq Rule 5605(a)(2) and Rule 10A-3(b)(1) of the Securities Exchange Act of 1934.
Management Commentary and Compensation
Ms. Felix brings 30 years of experience in capital markets, public accounting, and the private sector. She currently serves as CEO, CFO, and board member of BioCorRx Inc. and is an independent director at Avalon GloboCare Corp. In connection with her appointment, the Company entered into a Director Agreement (Exhibit 10.1). Ms. Felix will receive a non-refundable base fee of $12,000 per quarter, plus an additional quarterly fee of $3,750 for serving as Chairperson of the Audit Committee.
Key Facts for Investor Verification
- Verify the effective date of Ms. Felix's appointment (April 19, 2024) and her tenure until the next annual meeting.
- Review the Director Agreement filed as Exhibit 10.1 for full terms of engagement.
- Confirm that the resignation of Thomas Stringer was not related to any undisclosed disagreements or regulatory issues.
- Note that the filing contains no financial performance data; investors should refer to the most recent 10-Q or 10-K for financial metrics.